Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Enregistré dans:
Auteurs principaux: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Langue: | anglais |
Publié: |
Philipps-Universität Marburg
2023
|
Sujets: | |
Accès en ligne: | Texte intégral en PDF |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
No abstracts were found for this record.